Photo from archive.org
At therapeutic concentrations, AM0010 stimulates the cytotoxicity, survival and proliferation of intratumoral antigen activated CD8+ T cells in pre-clinical cancer models and in patients. AM0010 activates antigen stimulated CD8 T… Click to show full abstract
At therapeutic concentrations, AM0010 stimulates the cytotoxicity, survival and proliferation of intratumoral antigen activated CD8+ T cells in pre-clinical cancer models and in patients. AM0010 activates antigen stimulated CD8 T cells while PD-1 inhibits them. This provides the rationale for combining AM0010 and an anti-PD1. AM0010 monotherapy induced durable objective responses in ocular melanoma and renal cell cancer. AM0010 alone or in combination with chemotherapy and anti-PD1 has been well tolerated in this Phase 1 basket trial. Efficacy and Immune Activation with PEGylated human IL-10 (AM0010) in Combination with an anti-PD1 in Advanced NSCLC Update
Journal Title: Annals of Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!